|
FDA Green-Lights ViroPharma’s Cinryze, rHUPH20 Studies
The FDA is allowing ViroPharma and Halozyme Theraputics to move forward with clinical studies of subcutaneous Cinryze in combination with the human hyaluronidase enzyme rHuPH20 to prevent angioedema attacks.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives